ArticleFrontiers in oncology2020
Oncogenic Network and Hub Genes for Natural Killer/T-Cell Lymphoma Utilizing WGCNA.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Identification and Functional Investigation of Hub Genes Associated with Follicular Lymphoma.Biochemical genetics · 2025Article
- Analysis of prognostic biomarker models and immune microenvironment in acute myeloid leukemia by integrative bioinformatics.Journal of cancer research and clinical oncology · 2023Article
- Psoriasis Associated Hub Genes Revealed by Weighted Gene Co-Expression Network Analysis.Cell journal · 2023Article
- Intestinal natural killer/T-cell lymphoma presenting as a pancreatic head space-occupying lesion: A case report.World journal of gastrointestinal oncology · 2023Article
- Predicting leukemic transformation in myelodysplastic syndrome using a transcriptomic signature.Frontiers in genetics · 2023Article
- Microfluidic live tracking and transcriptomics of cancer-immune cell doublets link intercellular proximity and gene regulation.Communications biology · 2022Article
- Identification of a Signature for Predicting Prognosis and Immunotherapy Response in Patients with Glioma.Journal of oncology · 2022Article
- Identification and Validation of Novel Biomarkers for Hepatocellular Carcinoma, Liver Fibrosis/Cirrhosis and Chronic Hepatitis B via Transcriptome Sequencing Technology.Journal of hepatocellular carcinoma · 2022Article
- Article
- Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapy.Journal of translational medicine · 2021Article
- Identification and Validation of Key Genes of Differential Correlations in Gastric Cancer.Frontiers in cell and developmental biology · 2021Article
- High Expression ofFrontiers in oncology · 2021Article
- Weighted correlation network bioinformatics uncovers a key molecular biosignature driving the left-sided heart failure.BMC medical genomics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK)/T-cell lymphoma (NKTCL) is a subtype of non-Hodgkin lymphoma with aggressive progression and poor prognosis. The molecular mechanisms of NKTCL have not been well-studied. Herein, we revealed the lymphoma-associated dysregulated genes and signaling pathways or biological processes in NKTCL. We characterized that the extracellular matrix (ECM) receptor interaction pathway and T-cell receptor signaling pathway were the main dysregulated pathways in NKTCL by Gene Ontology (GO) analysis and pathway enrichment analysis. By using weighted gene co-expression network analysis (WGCNA), the gene co-expression network of NKTCL (SRP049695) was constructed, and hub genes (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.